Vivatides Therapeutics Raises $54M to Advance Extrahepatic RNA Therapies

Oversubscribed Series A financing to accelerate platform development and pipeline expansion beyond the liver.

Apr. 10, 2026 at 12:52pm

Got story updates? Submit your updates here. ›

A photorealistic studio still-life image featuring a polished glass vial filled with a glowing liquid, representing the innovative extrahepatic RNA delivery technology developed by Vivatides Therapeutics. The vial is placed on a clean, monochromatic background, using dramatic lighting to convey a sense of precision and scientific progress.Vivatides Therapeutics' proprietary extrahepatic RNA delivery platform aims to unlock the potential of RNA therapeutics beyond the liver, paving the way for innovative treatments across a wide range of chronic diseases.Boston Today

Vivatides Therapeutics, a biotechnology company focused on extrahepatic RNA therapeutics, has closed a $54 million Series A financing round co-led by Qiming Venture Partners and a leading industry fund. The proceeds will be used to further advance Vivatides' extrahepatic delivery platform, accelerate multiple pipeline programs into clinical development, and expand its global team and R&D network.

Why it matters

Overcoming delivery challenges to target tissues beyond the liver is a key frontier for the RNA therapeutics field, unlocking potential treatments for a wide range of chronic diseases. Vivatides' proprietary platform aims to enable the expansion of RNA-based medicines into large, underserved extrahepatic disease areas.

The details

Vivatides has built a differentiated extrahepatic RNA delivery platform with capabilities spanning both siRNA and antisense oligonucleotides (ASO). The company has achieved advances in ligand conjugation, delivery efficiency, tissue targeting specificity, and safety, with encouraging in vivo results already demonstrated. Combined with strong capabilities in sequence design and target discovery, the platform enables rapid parallel advancement and expansion of a diversified pipeline.

  • Vivatides Therapeutics was founded in 2025.
  • The company completed its Series A financing in April 2026.

The players

Vivatides Therapeutics

A global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics.

Qiming Venture Partners

A leading venture capital firm that co-led Vivatides' Series A financing.

Keming Zhou

The founder of Vivatides Therapeutics.

Kan Chen

A partner at Qiming Venture Partners who co-leads the firm's investments in the healthcare sector.

Wei Ding

A partner at Apricot Capital, an existing investor that continued to support Vivatides with additional investment.

Got photos? Submit your photos here. ›

What they’re saying

“Extrahepatic delivery is the key that will unlock RNA therapeutics from niche rare diseases to broad chronic indications. We are honored to have the support and recognition of leading investors. This financing will accelerate the evolution of our platform and pipeline, advancing innovative RNA therapeutics into extrahepatic disease areas.”

— Keming Zhou, Founder of Vivatides Therapeutics

“We have long been optimistic about the application potential of small nucleic acid drugs across a broader range of disease areas. Continuous advances in extrahepatic targeting technologies are steadily expanding their clinical frontiers. Vivatides Therapeutics has demonstrated solid technological expertise and efficient execution capabilities in this field, with encouraging progress achieved on its platform.”

— Kan Chen, Partner at Qiming Venture Partners

“As an early investor in Vivatides' seed round, we are delighted to see the company successfully complete its Series A financing and welcome new investors. Since its founding, Dr. Zhou and his team have consistently exceeded expectations with exceptional execution in platform development and pipeline advancement.”

— Wei Ding, Partner at Apricot Capital

What’s next

Vivatides will further accelerate preclinical optimization and IND-enabling studies, expand its R&D and management teams, and continue to strengthen its extrahepatic delivery platform.

The takeaway

Overcoming the delivery challenges to target tissues beyond the liver is a key frontier for the RNA therapeutics field, unlocking the potential to treat a wide range of chronic diseases. Vivatides' proprietary platform aims to enable the expansion of RNA-based medicines into large, underserved extrahepatic disease areas.